Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2016

Open Access 01-12-2016 | Research

Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”

Authors: B. Bienvenu, G. Cozon, C. Hoarau, M. Pasquet, P. Cherin, P. Clerson, E. Hachulla, J. C. Crave, J. C. Delain, R. Jaussaud

Published in: Orphanet Journal of Rare Diseases | Issue 1/2016

Login to get access

Abstract

Background

IgG replacement therapy (IgRT) in primary immunodeficiencies (PID) is a lifelong treatment which may be administered intravenously (IVIg) or subcutaneously (SCIg), at hospital or at home. The objective of the VISAGE study was to investigate if route and/or place for IgRT impact patients’ satisfaction regarding IgRT and quality of life (QoL) in real-life conditions.

Methods

The study enrolled PID patients at least 15 years old receiving IgRT for at least 3 months. Satisfaction and QoL were evaluated at enrollment and over a 12-month follow-up period by Life Quality Index (LQI) which measures 3 dimensions of satisfaction: treatment interference, therapy related problems and therapy settings (factors I, II and III) and SF-36 v2 questionnaire.

Results

The study included 116 PID patients (mean age 42 ± 18 years, 44 % males, 58 % with scholar or professional occupation) receiving IgRT for a mean of 8.5 ± 8.4 years. At enrollment they were receiving either home-based SCIg (51 %), hospital-based IVIg (40 %) or home-based IVIg (9 %). Patients exhibited a high degree of satisfaction regarding IgRT whatever the route and place for administration. LQI factor I was higher for home-based SCIg (86 ± 2) than for hospital-based IVIg (81 ± 3) and home-based IVIg (73 ± 5; p = 0.02 versus home-based SCIg); no difference was found for LQI factor II; LQI factor III was higher for home-based SCIg (92 ± 2) than for hospital-based IVIg (87 ± 5) and hospital-based IVIg (82 ± 3; p = 0.005 versus home-based SCIg). By contrast, every dimension of QoL was impaired. Over the follow-up period, 10 patients switched from hospital-based IVIg to home-based SCIg and improved LQI factor I (p = 0.004) and factor III (p = 0.02), while no change was noticed in LQI factors II and QoL. Meanwhile, no change in satisfaction or QoL was found in patients with stable route of IgRT. When asked on their preferred place of treatment all but one patient with home-based treatment would choose to be treated at home and 29 % of patients treated at hospital would prefer home-based IgRT.

Conclusion

PID patients expressed a high degree of satisfaction regarding IgRT, contrasting with impaired QoL. In real-life conditions awareness of patient’s expectations regarding the route or place of IgRT may be associated with further improvement of satisfaction.
Literature
1.
Champi C. Primary immunodeficiency disorders in children: prompt diagnosis can lead to lifesaving treatment. J Pediatr Health Care. 2002;16(1):16–21.CrossRefPubMed
2.
Tcheurekdjian H, Palermo T, Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol. 2004;93(2):160–5.CrossRefPubMed
3.
Gardulf A et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936–42.CrossRefPubMed
4.
Mozaffari H et al. Health-related quality of life in primary immune deficient patients. Iran J Allergy Asthma Immunol. 2006;5(1):23–7.PubMed
5.
Soresina A et al. The quality of life of children and adolescents with X-linked agammaglobulinemia. J Clin Immunol. 2009;29(4):501–7.CrossRefPubMed
6.
Kuburovic NB et al. Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies. Patient Prefer Adherence. 2014;8:323–30.CrossRefPubMedPubMedCentral
7.
Tabolli S et al. Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies. Front Immunol. 2014;5:605.CrossRefPubMedPubMedCentral
8.
Zebracki K et al. Health-related quality of life of children with primary immunodeficiency disease: a comparison study. Ann Allergy Asthma Immunol. 2004;93(6):557–61.CrossRefPubMed
9.
Jiang F, Torgerson TR, Ayars AG. Health-related quality of life in patients with primary immunodeficiency disease. Allergy, Asthma Clin Immunol. 2015;11:27.CrossRef
10.
Aguilar C et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis. 2014;59(10):1462–70.CrossRefPubMed
11.
12.
13.
Boyle ML, Scalchunes C. Impact of intravenous immunoglobulin (IVIG) treatment among patients with Primary Immunodeficiency diseases. Pharmaceuticals Policy Laws. 2008;10:133–46.
14.
Gardulf A et al. Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency. 1993;4(1-4):81–4.PubMed
15.
Nicolay U et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65–72.CrossRefPubMed
16.
Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6(6):434–42.CrossRefPubMed
17.
18.
Gardulf A et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study. J Clin Immunol. 2006;26(2):177–85.CrossRefPubMed
19.
Chapel HM et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94–100.CrossRefPubMed
20.
Fasth A, Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96(10):1474–8.CrossRefPubMed
21.
Gardulf A et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345(8946):365–9.CrossRefPubMed
22.
Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338(8760):162–6.CrossRefPubMed
23.
Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 1991;325(2):110–7.CrossRefPubMed
24.
Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol. 1994;14(2):90–7.CrossRefPubMed
25.
Gardulf A et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients’ experiences of subcutaneous self-infusions and home therapy. J Adv Nurs. 1995;21(5):917–27.CrossRefPubMed
26.
Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics. 1996;98(6 Pt 1):1127–31.PubMed
27.
Remvig L et al. Prophylactic effect of self-administered pump-driven subcutaneous IgG infusion in patients with antibody deficiency: a triple-blind cross-over study comparing P-IgG levels of 3 g l-1 versus 6 g l-1. J Intern Med. 1991;229(1):73–7.CrossRefPubMed
28.
Wasserman RL. Hizentra for the treatment of primary immunodeficiency. Expert Rev Clin Immunol. 2014;10(10):1293–307.CrossRefPubMed
29.
Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013;73(12):1307–19.CrossRefPubMed
30.
31.
Espanol T et al. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adherence. 2014;8:621–9.CrossRefPubMedPubMedCentral
32.
Nicolay U et al. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res. 2005;14(7):1683–91.CrossRefPubMed
33.
IRIS A. Enquête sur le traitement substitutif en immunoglobulines auprès de patients atteints de déficits immunitaires primitifs. 2006.
34.
Gathmann B et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol. 2009;157 Suppl 1:3–11.CrossRefPubMedPubMedCentral
35.
Knerr V et al. The ESID Online Database for primary immunodeficiencies. First analyses with regard to Germany and Europe. Med Klin (Munich). 2008;103(9):620–7.CrossRef
36.
Weaver M et al. Issues in the measurement of satisfaction with treatment. Am J Manag Care. 1997;3(4):579–94.PubMed
37.
Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1–10.CrossRefPubMedPubMedCentral
38.
Gardulf A et al. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol. 2008;126(1):81–8.CrossRefPubMed
39.
Al-Herz W et al. Performance status and deaths among children registered in Kuwait National Primary ImmunoDeficiency Disorders Registry. Asian Pac J Allergy Immunol. 2010;28(2-3):141–6.PubMed
40.
Vultaggio A et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig. 2015;35(3):179–85.CrossRefPubMedPubMedCentral
41.
Hoffmann F et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15(6):238–45.PubMedPubMedCentral
Metadata
Title
Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”
Authors
B. Bienvenu
G. Cozon
C. Hoarau
M. Pasquet
P. Cherin
P. Clerson
E. Hachulla
J. C. Crave
J. C. Delain
R. Jaussaud
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2016
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-016-0452-9

Other articles of this Issue 1/2016

Orphanet Journal of Rare Diseases 1/2016 Go to the issue

Research

Analysis of voice quality in patients with late-onset Pompe disease

Letter to the Editor

Proteus syndrome: evaluation of the immunological profile

Review

The P42 peptide and Peptide-based therapies for Huntington’s disease

Research

Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China

Research

Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantation

Research

Mucopolysaccharidosis I; Parental beliefs about the impact of disease on the quality of life of their children